ClinicalTrials.gg
Not yet recruitingNCT06556264Updated Aug 16, 2024

Immunologic Impact of Dupilumab in Patients Suffering From Asthma and Chronic Rhinosinusitis With Polyps

A Phase 4 interventional study of Dupilumab and Placebo in Chronic Rhinosinusitis With Nasal Polyps and Asthma, sponsored by Dr. Andrew Thamboo, MD. Not yet recruiting. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2024-08-16.

Sponsored by Dr. Andrew Thamboo, MD · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jan 2025, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 31 studies testing dupilumab in Asthma — 7 open to participants now, 12 under way, 2 of them phase 3. dupilumab · Asthma.

Planned enrollment
22nd of 31
60 · median 120
Started
2024
with 4 others
Phase 4
14 of 31
5 open now
Primary completion
2025-01
later than 0 of 11 live
Registered
28th of 31
by date
Lead sponsor
1 of 31
Dr. Andrew Thamboo, MD

Among the 31 studies testing dupilumab in Asthma, this one is the 22nd largest by planned enrollment, is one of 5 that started in 2024, is one of 14 in phase 4, reaches primary completion later than 0 of the 11 other live ones, and was the 28th registered.

Asthma

4,846 studies on the registry are indexed under Asthma; 605 are open to participants now.

Browse Asthma studies →

Open to participants now

7 of the 31 studies testing dupilumab in Asthma are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About dupilumab

dupilumab: first FDA approval 2017 (DUPIXENT), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies testing dupilumab in Asthma, or all of them as a file.
02

Study summary

The investigators are studying adults who have chronic rhinosinusitis with nasal polyps (CRSwNP) and moderate to severe asthma, and who are undergoing Endoscopic Sinus Surgery (ESS). Investigators want to understand how adding a medication called dupilumab to their usual treatment affects inflammation in their upper and lower airways over 24 weeks.

Dupilumab works by blocking certain signals in the immune system that contribute to inflammation in both the sinuses and the lungs. By studying how this medication changes the immune profiles of both airway systems, investigators hope to learn more about the underlying causes of airway inflammation in these conditions.

This research is important because it may help understand if treating inflammation in one part of the airway (like the lungs) has a similar effect on inflammation in another part (like the sinuses). This could lead to better treatments for people with CRSwNP and asthma, targeting the root causes of their symptoms more effectively.

Read the detailed description

In adult patients with CRSwNP with concomitant moderate-severe asthma undergoing Endoscopic Sinus Surgery (ESS), what is the change in the inflammatory cascade in the upper and lower airways from patients treated with 300 mg of dupilumab twice daily for 24 weeks as an add-on treatment to the standard of care (intranasal corticosteroids, INCS+ backgroung asthma medication) compare to the placebo + standard of care treatment only.

The investigators hypothesize that the study of the immune profile in patients with CRSwNP and asthma would give a better understanding of the mechanism involved in the airway inflammatory response. Determining the molecular profiles of the upper and lower airways after dupilumab treatment has not been studied yet.

Dupilumab has demonstrated effectiveness in treating both Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) and asthma, conditions characterized by Type 2 inflammation, by inhibiting the IL-4 and IL-13 signalling pathways. However, it remains unclear how immunological changes occur in paired tissues of the upper (sinus) and lower (lung) airways in patients treated with biologics compared to those receiving standard therapies. Additionally, it is not well understood whether improvements in one airway system (e.g., the lungs) are mirrored in the other (e.g., the sinuses), which could result in differing clinical responses. This study aims to address these gaps by examining the comparative effects of Dupilumab versus standard treatments on both airway systems, to determine if therapeutic effects are consistently observed across both systems and to understand the potential implications for clinical responsiveness.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
  • Asthma

Browse trials for

04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients over the age of 19.
  • Patients undergoing Endoscopic Sinus Surgery (ESS)
  • Patients with CRSwNP with moderate-severe asthma according to 2020 EPOS criteria:

    1. Asthma confirmed with spirometry and assessment on the previous history of asthma (a methacholine challenge test and atopy testing to document the positive or negative history of asthma will be performed if there is no clinical record). Asthma severity based on GINA guidelines.
    2. Presence of nasal polyps. This can be based on the formal exam at Baseline Visit or historical assessment.

Exclusion criteria

Exclusion Criteria:

  • Patients with current or past sinonasal or bronchial tumours
  • Subjects who have been treated with oral antibiotics in the past month prior to surgery
  • Subjects with known immunodeficiency
  • Subjects with known disease
  • Subjects with other sinonasal diseases other than CRSwNP (e.g., cystic fibrosis, eosinophilic granulomatosis with polyangiitis, allergic fungal rhinosinusitis, invasive fungal sinusitis, fungal ball, dyskinetic cilia syndrome)
  • Prior lung transplants
  • Subjects with ; with allergy/intolerance to a monoclonal antibody or biologic
  • Prior use of dupilumab or other biologic medications (omalizumab. mepolizumab, reslizumab,etc) 6 months before enrollment.
  • Any condition that, in the opinion of the investigator, may interfere with the patient's ability to participate in the study per protocol.
  • Participation in an ongoing interventional or observational study using a biologic treatment.
  • Female participants who are pregnant or breastfeeding
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (estimated)

Study arms

  • Active comparator
    Dupilumab

    30 subjects undergoing ESS + dupilumab 300 (1-week post-surgery) every 2 weeks + standard of care treatment (INCS + background asthma medication) for 24 weeks

    Drug: Dupilumab

  • Placebo comparator
    Placebo

    30 subjects undergoing ESS + placebo (1-week post-surgery) every 2 weeks + standard of care treatment (INCS + background asthma medication) for 24 weeks.

    Other: Placebo

Interventions

  • Dupilumab 300mg every 2 weeks for 24 weeks

    Also known as: dupixent

  • OtherPlacebo

    Placebo 300mg every 2 weeks for 24 weeks

06

What researchers measure

Primary outcomes

  1. Change in Cytokine levels such as GM-CSF, IFNg, TNFa, VEGF-A, Identification of Key Interleukins and chemokynes (10/CXCL10, MIP-1a/CCL3, RANTES/CCL5), compared with placebo in CRSwNP and asthma patients from baseline to week 24

    Change in GM-CSF, IFNg, IL-1b, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12 (p40), IL-13, IL-17A, IP-10/CXCL10, MIP-1a/CCL3, RANTES/CCL5, TNFa, VEGF-A compared with placebo in CRSwNP and asthma patients from baseline to week 24

    Time frame: From baseline to 24 weeks.

Secondary outcomes

  1. Changes in SNOT-22, ACQ-5 and Sniffin Stick Test

    Relation of changes in the inflammatory profiles with changes in symptom control (SNOT-22, ACQ-5,Sniffin Stick test) compared with placebo at baseline and 24 weeks.

    Time frame: 24 weeks

  2. Relation of changes in inflammatory profile with changes in endoscopic scores (MLK)

    Correlate the changes in the inflammatory profiles with changes in endoscopy scores (MLK scores) compared with placebo at baseline and 24 weeks.

    Time frame: 24 weeks

  3. Relation of inflammatory profile and (FeNO and nasal FeNO)

    Correlate the changes in the inflammatory profiles with changes in the pulmonary function measured by spirometry FEV1 values and standard and nasal fractional exhaled nitric oxide (FeNO and nasal FeNO) compared with placebo at baseline and 24 weeks

    Time frame: 24 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Jan 2025, 5 months later.

Of 90 non-industry phase 4 interventional studies under Asthma, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 51. This study's planned 5 months is below that.

Counting every sponsor, half of 156 studies reached it within 24 months; a quarter within 11 and three quarters within 37.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 8, 2024
First posted
Aug 16, 2024
StartEst.
Aug 2024
Primary completionEst.
Jan 2025
CompletionEst.
Dec 2025
Last update
Aug 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06556264
Lead sponsor
Dr. Andrew Thamboo, MD
Collaborators
Sanofi
Responsible party
Dr. Andrew Thamboo, MD (Clinical Assistant Professor, St. Paul's Sinus Centre) — Sponsor-investigator
First posted
Aug 16, 2024
Start date
Aug 2024 (estimated)
Primary completion
Jan 2025 (estimated)
Completion
Dec 2025 (estimated)
Last update
Aug 16, 2024

Study contacts

Andrew Thamboo
Contact
andrew.thamboo@gmail.com
604-250-4174
Leonora Beltran
Contact
lbeltranjimenez@providencehealth.bc.ca
604-250-4174
Andrew Thamboo
principal investigator · St Paul's Sonis Centre Director

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion